The Structure of DNA-Bound Human Topoisomerase II Alpha: Conformational Mechanisms for Coordinating Inter-Subunit Interactions with DNA CleavageMyeloperoxidase Enhances Etoposide and Mitoxantrone-Mediated DNA Damage: A Target for Myeloprotection in Cancer ChemotherapygammaH2AX foci form preferentially in euchromatin after ionising-radiation.The impact of the human DNA topoisomerase II C-terminal domain on activity.The impact of the C-terminal domain on the interaction of human DNA topoisomerase II α and β with DNA.Molecular cloning and characterization of the human topoisomerase IIalpha and IIbeta genes: evidence for isoform evolution through gene duplication.Isolation and characterization of a human cDNA clone encoding a novel DNA topoisomerase II homologue from HeLa cells.Novel HeLa topoisomerase II is the II beta isoform: complete coding sequence and homology with other type II topoisomerases.Poly(ADP-ribose) polymerases PARP1 and PARP2 modulate topoisomerase II beta (TOP2B) function during chromatin condensation in mouse spermiogenesis.Histone deacetylase inhibition redistributes topoisomerase IIβ from heterochromatin to euchromatinBrief reports: Controlling the survival of human pluripotent stem cells by small molecule-based targeting of topoisomerase II alpha.Differential Targeting of Human Topoisomerase II Isoforms with Small Molecules.Schedule-dependent response of neuroblastoma cell lines to combinations of etoposide and cisplatin.An overview of the visualisation and quantitation of low and high MW DNA adducts using the trapped in agarose DNA immunostaining (TARDIS) assay.Mechanism of generation of therapy related leukemia in response to anti-topoisomerase II agents.Kinetic analysis of human topoisomerase IIalpha and beta DNA binding by surface plasmon resonance.Genome-wide ChIP-seq analysis of human TOP2B occupancy in MCF7 breast cancer epithelial cells.Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.Human Tra2 proteins jointly control a CHEK1 splicing switch among alternative and constitutive target exons.The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA cleavage and is selective for the α isoform.Human DNA topoisomerase IIbeta binds and cleaves four-way junction DNA in vitro.H2AX phosphorylation as a genotoxicity endpoint.NK314, a topoisomerase II inhibitor that specifically targets the alpha isoform.Distinct expression patterns for type II topoisomerases IIA and IIB in the early foetal human telencephalon.The role of topoisomerase II in the excision of DNA loop domains during apoptosis.Structure and partial amino acid sequence of calf thymus DNA topoisomerase II: comparison with other type II enzymes.Formation and longevity of idarubicin-induced DNA topoisomerase II cleavable complexes in K562 human leukaemia cells.Differences in the longevity of topo IIalpha and topo IIbeta drug-stabilized cleavable complexes and the relationship to drug sensitivity.A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia.Mutation P732L in human DNA topoisomerase IIbeta abolishes DNA cleavage in the presence of calcium and confers drug resistance.The novel poly(ADP-Ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks.Curcumin induces high levels of topoisomerase I- and II-DNA complexes in K562 leukemia cells.Digitoxin, at concentrations commonly found in the plasma of cardiac patients, antagonizes etoposide and idarubicin activity in K562 leukemia cells.Topoisomerase II Chromatin Immunoprecipitation.sox30: a novel zebrafish sox gene expressed in a restricted manner at the midbrain-hindbrain boundary during neurogenesis.Position-specific effects of base mismatch on mammalian topoisomerase II DNA cleaving activity.Visualization and Quantification of Topoisomerase-DNA Covalent Complexes Using the Trapped in Agarose Immunostaining (TARDIS) Assay.Plant and Human MORC Proteins Have DNA-Modifying Activities Similar to Type II Topoisomerases, but Require One or More Additional Factors for Full Activity.
P50
Q27670934-564E7778-B833-4FAD-8C35-1CE7CE598B62Q28818421-F0B9BB65-D2FD-4DA4-B5DC-1ED23F02816AQ33303665-605BDB82-DE9C-47A4-AE05-F273E823BF0EQ33323361-DC30BC91-E66B-480B-87DF-304C2005553DQ33831806-5472E074-D1B4-4BD1-B809-8843B781F004Q33856408-81940D56-069F-4301-8358-F665698EB5D8Q33921680-2D3FFA6B-A658-44D1-835C-9C766A6A13AEQ34355492-F98E62E5-D536-42B4-ADB3-5F2E68563BCEQ34826930-40212F2E-C1A7-47F2-A131-37DF23B618B9Q35015901-E6DDD4B7-F1C1-43E9-A581-050FFF8067A4Q35401202-FDE39769-3EDF-4052-98D4-8AEA277AEADDQ35622993-71C33EAD-407B-4760-B79F-F7D2F2C13711Q36643776-D67AFF9E-2D11-4EC7-AC9C-7F4B32AB9682Q37808574-CCA3905D-CBF1-4053-BC65-232EBD8A7D5BQ38029323-B3C16FEA-CDB4-4B31-94A2-C18594C91691Q38348474-FFB06097-8BDB-4589-B43A-1C4297F5A68EQ38456475-4BB167C7-9981-4067-AE2F-849F08A4CC9EQ38801085-EB74CFD3-CF78-47B1-AC7A-CAFCFEA18850Q38957719-F74A5F09-E96E-4E6E-A295-9AE1A8891D9AQ39044567-A9D5F968-68CD-465D-95B9-DA3BBF4B6BF1Q39064022-F59D9766-9315-45F7-B9B4-FE8B74C6635FQ39727210-0C208FBE-F968-47CD-9080-0CC76EF2CEA1Q39821608-548A4A6D-580E-4EF4-88B4-DA1582745D39Q40075000-0BF49251-7125-42EA-9191-2FAB3961A892Q40196610-4DA5A5FB-6306-4E16-AC56-8E32F0762095Q40739485-EDD9159E-F861-40D2-BF80-F1A5309065F1Q42615429-09FA4573-B14C-4E0A-AF2F-38545F214401Q44009060-CA1E0E7C-45FE-4B97-85D2-6D82B62CFB9DQ44593211-272C3F2E-36A3-4B57-8E47-9D5CD287E0DBQ44699661-D8A22516-D423-4CEE-A5CF-A97B168BF1B6Q46535643-B01FDA64-B6A8-4D10-82C2-BDE31C335F24Q46766155-C637505A-F8EC-4BD5-9C9E-65AD23291500Q46831119-8C58544C-59E3-4036-AABA-1F920A01D1D9Q46853387-19FEBCEB-8DB9-4A2D-A4E8-FF587FFC48CFQ46874789-0BD43EC1-0DE5-4E90-9276-F36D885F106FQ47362326-7E5C8183-F5A5-4645-A7B9-B90047BC9590Q47955582-4D916302-9BB4-4784-90B4-56E73137A474Q48066983-AC6A5FDD-D184-4F8D-8F6F-5D28701B2E59Q49607557-ACA900C1-557C-4B9E-8599-D84EA772EDFEQ51251291-76E960E7-DDFC-4A50-948D-665E201E6A57
P50
description
bioloog
@nl
researcher ORCID ID = 0000-0002-1921-5947
@en
name
Caroline Ann Austin
@ast
Caroline Ann Austin
@de
Caroline Ann Austin
@en
Caroline Ann Austin
@es
Caroline Ann Austin
@nl
type
label
Caroline Ann Austin
@ast
Caroline Ann Austin
@de
Caroline Ann Austin
@en
Caroline Ann Austin
@es
Caroline Ann Austin
@nl
altLabel
Caroline A Austin
@ast
Caroline A Austin
@en
Caroline A Austin
@es
Caroline A Austin
@nl
Caroline Austin
@ast
Caroline Austin
@en
Caroline Austin
@es
Caroline Austin
@nl
prefLabel
Caroline Ann Austin
@ast
Caroline Ann Austin
@de
Caroline Ann Austin
@en
Caroline Ann Austin
@es
Caroline Ann Austin
@nl
P106
P1153
7201681491
P1960
HwmY41kAAAAJ
P2038
Caroline_Austin2
P2080
P21
P31
P496
0000-0002-1921-5947